When an emerging biotech developing a first-in-class, best-in-class therapy for von Willebrand disease (VWD) partnered with Worldwide, they faced a challenge: to quickly identify the optimal dose for their upcoming study.
A few key achievements to highlight:
- Met enrollment goals despite challenges
- Delivered data for DMC review within 10 days
- Activated the first OLE site within 32 days
Read the full case study to learn how our flexible solutions can optimize your next Phase 1b study.
